89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... [Yahoo! Finance]
89bio, Inc. (ETNB)
Last 89bio, inc. earnings: 3/18 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
R&D Expenses : R&D expenses rose to $33.6 million for Q4 and $122.2 million for the full year, reflecting increased investment in clinical programs. G&A Expenses : G&A expenses increased to $7.6 million for Q4 and $29.0 million for the full year, due to personnel growth and professional service fees. Net Loss : Net loss widened to $40.2 million for Q4 and $142.2 million for the full year, driven by higher R&D and G&A expenses. Clinical Development : Positive Phase 2b ENLIVEN trial results and preparations for Phase 3 trials in NASH and ongoing SHTG trial. Warning! GuruFocus has detected 2 Warning Sign with ETNB. On February 29, 2024, 89bio Inc ( NASDAQ:ETNB ) released its 8-K filing , detailing the financial results for the fourth quarter and full year of 2023, along with providing updates on corporate milestones. As a clinical-stage biopharmaceutical company, 89bio is at the forefront of developing therapies for liver and cardio-metabolic diseases, with a particular focus
Show less
Read more
Impact Snapshot
Event Time:
ETNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETNB alerts
High impacting 89bio, Inc. news events
Weekly update
A roundup of the hottest topics
ETNB
News
- 89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH [Yahoo! Finance]Yahoo! Finance
- 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASHGlobeNewswire
- 89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.MarketBeat
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of DirectorsGlobeNewswire
ETNB
Earnings
- 11/8/23 - Beat
ETNB
Sec Filings
- 5/3/24 - Form 4
- 4/23/24 - Form 3
- 4/19/24 - Form ARS
- ETNB's page on the SEC website